Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dinoprostone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 known ✓ | P35408 | 5/20 | 1.00 |
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER3 known ✓ | P43115 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 3/20 | 1.00 |
| ▸ | PTGIR | P43119 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGFR | P43088 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dinoprostone SCHEMBL24340817 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23909398 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23353214 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352922 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352614 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24223591 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24727254 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352819 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352791 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352988 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102123586-A | Methods of treating overweight or obese subjects | ZAFGEN INC | 2011-07-13 | — | — | CN | claimed |
| EP-2317845-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | Zafgen, Inc. (US) | 2011-05-11 | — | — | EP | claimed |
| WO-2010009374-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11517608-B2 | Peptide-containing formulations | COHBAR, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20220280470-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | SYNDEVRX, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4013440-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-102123586-A | Methods of treating overweight or obese subjects | ZAFGEN INC | 2011-07-13 | — | — | CN | disclosed |
| EP-2317845-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | Zafgen, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010065877-A2 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN CORPORATION (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065881-A2 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN CORPORATION (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065883-A2 | METHOD OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN CORPORATION (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065879-A2 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN CORPORATION (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010009374-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016425-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | ZAFGEN, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280470-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | PCK2, PC, GOT2 | PTGER4 4714/4885PTGER2 4038/4885PTGER3 4774/4885 |
| US-20220175749-A1 | LANABECESTAT FOR WEIGHT LOSS | GIPR, GLP1R, IGF1R | PTGER4 2982/4885PTGER2 3526/4885PTGER3 3901/4885 |
| US-20100016425-A1 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT | LIPC, FABP4, LPL | PTGER4 765/4885PTGER2 830/4885PTGER3 579/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | PTGER4 4838/4885PTGER2 4023/4885PTGER3 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.